NCT00442962View on ClinicalTrials.gov

HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

December 31, 2010

Conditions
HIV Infections
Interventions
DRUG

Efavirenz

600-mg tablet taken orally daily

DRUG

Emtricitabine/Tenofovir disoproxil fumarate

200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily

Trial Locations (9)

18

Barranco CRS, Lima

10011

Weill Med. College of Cornell Univ., The Cornell CTU -Chelsea, New York

10457

Bronx-Lebanon Hosp. Ctr. CRS, The Bronx

21045

Instituto de Pesquisa Clinica Evandro Chagas Fiocruz, Fundacao Oswaldo Cruz, Rio de Janeiro

27514

University of North Carolina, Chapel Hill

63108

Washington University School of Medicine, St Louis

92103

Ucsd, Avrc, San Diego

02115

Brigham and Women's Hospital, Division of Infectious Disease, Boston

Unknown

San Miguel CRS, San Miguel

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

NCT00442962 - HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV | Biotech Hunter | Biotech Hunter